Filing Details

Accession Number:
0001209191-20-060395
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-24 20:00:14
Reporting Period:
2020-11-23
Accepted Time:
2020-11-24 20:00:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1478320 Adaptive Biotechnologies Corp ADPT Biological Products, (No Disgnostic Substances) (2836) 270907024
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1799081 L Stacy Taylor C/o Adaptive Biotechnologies
1551 Eastlake Ave E Ste 200
Seattle WA 98102
Svp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-23 1,109 $7.80 2,409 No 4 M Direct
Common Stock Acquisiton 2020-11-23 1,771 $6.55 4,180 No 4 M Direct
Common Stock Disposition 2020-11-23 23 $45.69 4,157 No 4 S Direct
Common Stock Disposition 2020-11-23 2,857 $46.31 1,300 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-11-23 1,109 $0.00 1,109 $7.80
Common Stock Stock Option (Right to Buy) Disposition 2020-11-23 1,771 $0.00 1,771 $6.55
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,926 2029-04-23 No 4 M Direct
28,334 2028-04-24 No 4 M Direct
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.
  2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $46.02 to 46.79, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
  3. The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
  4. The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.